ad image

Company Info

Sanofi

Sanofi

Drug Discovery & Development

Overview

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
Sanofi
Contributions
24 Contributions1 / 2
Sanofi
COVID-19 Vaccine

Sanofi and GSK COVID-19 Vaccine Candidate Demonstrates Strong Immune Responses Across All Adult Age Groups in Phase 2 Trial

Sanofi

PR-M05-21-011May 17, 2021
Sanofi
Vaccine Manufacturing

Sanofi to Help Manufacture Moderna's COVID-19 Vaccine

Sanofi

PR-M04-21-029-1015Apr 27, 2021
Sanofi
M&A

Sanofi Acquires Tidal Therapeutics and Adds an mRNA-Based Research Platform

Sanofi

PR-M04-21-012Apr 14, 2021
Sanofi
Manufacturing

Sanofi to Invest in Vaccine Production Site in Singapore

Sanofi

PR-M04-21-011Apr 13, 2021
Sanofi
COVID-19 Vaccine Funding

Sanofi and GSK Selected for Operation Warp Speed to Supply United States Government with 100 Million Doses of COVID-19 Vaccine

Sanofi

PR-M08-20-NI-05Jul 31, 2020
Sanofi
Strategic Partnership

Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

Sanofi

PR-M07-20-NI-013Jul 10, 2020
Sanofi
Collaboration

Sanofi and Translate Bio Expand Collaboration to Develop mRNA Vaccines Across All Infectious Disease Areas

Sanofi

PR-M06-20-NI-027Jun 23, 2020
Sanofi
FDA Approval

FDA Approves New Meningococcal Vaccination

Sanofi

PR-M04-20-NI-041Apr 28, 2020
Sanofi
COVID-19 Clinical Trial

Sanofi and Regeneron Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial in Hospitalized COVID-19 Patients

Sanofi

PR-M04-20-NI-040Apr 28, 2020
Sanofi
COVID-19 Self-Testing

Sanofi and Luminostics to Join Forces on Developing COVID-19 Smartphone-based Self-Testing Solution

Sanofi

PR-M04-20-NI-030Apr 20, 2020
Sanofi

Sanofi and GSK to Join Forces in COVID-19 Vaccine Collaboration

Sanofi

PR-M04-20-NI-020Apr 14, 2020
Sanofi
M&A

Sanofi to Acquire Synthorx to Bolster its Immuno-Oncology Pipeline for $2.5 Billion

Sanofi

PR-M12-19-NI-016Dec 10, 2019
Sanofi
Market Growth

Sanofi Delivered Solid Growth in Q2 2019

Sanofi

PR-M07-19-NI-077-2322Jul 30, 2019
Sanofi
Influenza

Sanofi Signs Strategic Deal for Exclusive US Over-the-Counter Rights to Tamiflu® in Flu Care

Sanofi

PR-M07-19-NI-061Jul 24, 2019
Sanofi
Patent

Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies

Sanofi

PR-M02-19-NI-059Feb 26, 2019
Sanofi
FDA Approval

FDA Approves Use of 0.5 mL Dose of Fluzone® Quadrivalent (influenza vaccine) in Children as Young as 6 Months of Age

Sanofi

PR-M01-19-NI-070Jan 24, 2019
Sanofi
Immuno-oncology

Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

Sanofi

PR-M01-19-NI-031Jan 10, 2019
Sanofi
Approval

FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma

Sanofi

PR-M10-18-NI-020Oct 04, 2018
Sanofi
Market Expansion

Sanofi to further accelerate its scientific presence with the opening of a Global R&D Operations Hub in Chengdu, China

Sanofi

PR-M07-18-NI-017Jul 06, 2018
Sanofi
Acquisition

Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure

Sanofi

PR-M06-18-NI-074Jun 22, 2018
1 / 2
0 Contributors1 / 0

No authors found

1 / 0